Status:
TERMINATED
ALF-STONE: Alfuzosin in Uretheric Stones
Lead Sponsor:
Sanofi
Conditions:
Prostatic Hyperplasia
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The aim of the study is to assess the effect of Alfuzosin compared with placebo, for 7 days, on the outcome of patients with uretheric stones submitted to Extracorporeal Shock Wave Lithotripsy (ESWL),...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with imagiologic evidence of uretheric stones
- Exclusion criteria:
- Women pregnant or breast feeding
- Patients with renal impairment (creatinine \> 2mg/dl)
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00454402
Start Date
August 1 2006
End Date
July 1 2007
Last Update
September 24 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Lisbon, Portugal